<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859752</url>
  </required_header>
  <id_info>
    <org_study_id>TR1801-CL-01</org_study_id>
    <nct_id>NCT03859752</nct_id>
  </id_info>
  <brief_title>TR1801-ADC in Patients With Tumors That Express c-Met</brief_title>
  <official_title>A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanabe Research Laboratories USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Open Innovation Partners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanabe Research Laboratories USA Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of
      TR1801-ADC in patients with select solid tumors that express c-Met.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First-in-human, Phase 1, multiple dose-dose escalation study designed to determine safety,
      tolerability, maximum tolerated dose, and recommended phase 2 dose of TR1801-ADC in patients
      with select solid tumors that express c-Met. This study will also assess pharmacokinetics
      (PK), anti-tumor activity, and correlation between clinical outcomes (safety, anti-tumor
      activity, and PK) and c-Met expression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, multiple dose, dose-escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants with treatment-related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish maximum tolerated dose</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with protocol-defined dose-limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetics of TR1801-ADC</measure>
    <time_frame>2 years</time_frame>
    <description>Analyze blood plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>2 years</time_frame>
    <description>Assess anti-drug antibodies of TR1801-ADC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate clinical activity of TR1801-ADC</measure>
    <time_frame>3 years</time_frame>
    <description>Assess objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST V1.1)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>TR1801-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TR1801-ADC</intervention_name>
    <description>Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin</description>
    <arm_group_label>TR1801-ADC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Compliance with all study procedures and visits to the clinical research site

          -  Locally advanced or metastatic disease that is not amenable to definitive therapy

          -  Histologically confirmed diagnosis of a solid tumor which expresses c-Met

          -  Must have progressed or have been intolerant to all available therapies known to
             confer clinical benefit appropriate for the patient's tumor type

          -  Measurable baseline disease as defined by RECIST Version 1.1

          -  ECOG Performance Status 0-1

          -  Body weight within 40 and 150 kg

          -  Clinical laboratory values with the limits as defined by the protocol

          -  Not pregnant or breast feeding

          -  Males and women of child-bearing potential must agree to use an effective method of
             contraception

        Exclusion Criteria:

          -  Any disease or condition that may be considered to pose an increased risk from study
             treatment or the ability of the patient to participate and comply with study
             procedures

          -  Treatment with anti-cancer therapy (including cytotoxic chemotherapy, major surgery,
             radiation, biologic and investigational agents) within 21 days before first dose of
             study treatment

          -  Brain metastases that has not stabilized for at least 28 days after therapy and who
             have discontinued steroids for &lt;2 weeks

          -  Unresolved adverse events &gt;= Grade 2 from prior anticancer therapies

          -  Acute myocardial infarction, cerebral ischemic infarct, or other arterial thrombosis
             within 6 months of screening for this study.

          -  Uncontrolled hypertension, unstable angina, or NYHA Class III/IV heart failure

          -  Untreated or uncontrolled bacterial, viral or fungal infection

          -  HIV infection or active infection with hepatitis B or C

          -  Prior treatment with a c-Met targeted agent

          -  Prior hypersensitivity reaction to treatment with another monoclonal antibody

          -  QTcF &gt;=470 ms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Carlson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tanabe Research Laboratories</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Herdener</last_name>
    <phone>(919) 972-7168</phone>
    <email>Nicole.Herdener@iqvia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Holly Schuster</last_name>
    <phone>(984) 204-1280</phone>
    <email>Holly.Schuster@iqvia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Rippke</last_name>
      <phone>720-848-0685</phone>
      <email>Sarah.Rippke@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Wells Messersmith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins - Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley O'Connor</last_name>
      <phone>410-502-2377</phone>
      <email>aoconnor@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Marrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington / Seattle Cancer Care</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Lee</last_name>
      <phone>206-606-7051</phone>
      <email>hpiek@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Kit Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibody-drug conjugate</keyword>
  <keyword>c-Met</keyword>
  <keyword>solid tumors</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

